• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

北爱尔兰黏多糖贮积症的发病率。

Incidence of the mucopolysaccharidoses in Northern Ireland.

作者信息

Nelson J

机构信息

King Edward Memorial Hospital, Perth, Western Australia.

出版信息

Hum Genet. 1997 Dec;101(3):355-8. doi: 10.1007/s004390050641.

DOI:10.1007/s004390050641
PMID:9439667
Abstract

An epidemiological study of the mucopolysaccharidoses (MPS) in Northern Ireland using multiple ascertainment sources was carried out and the incidence rate for the period 1958-1985 was estimated. An incidence of approximately 1 in 76,000 live births was obtained for MPS 1H (Hurler phenotype); 1 in 280,000 for MPS 1 H/S (Hurler/Scheie phenotype); 1 in 140,000 live births (1 in 72,000 male live births) for MPS II (Hunter syndrome); 1 in 280,000 for MPS III (Sanfilippo syndrome) and 1 in 76,000 for MPS IV A (Morquio syndrome type A). No cases of MPS IS (Scheie phenotype), MPS IV B (Morquio syndrome type B) or MPS VI (Maroteaux-Lamy syndrome) were ascertained during the study period. Three cases of non-immune hydrops fetalis born to consanguineous parents were thought to be due to beta-glucuronidase deficiency (MPS VII) on the basis of placental histology and enzyme studies on both parents but no living cases of MPS VII were ascertained. The overall incidence for all types of mucopolysaccharidosis was approximately 1 in 25,000 live births. A comparison is made with incidence estimates obtained from other published studies.

摘要

利用多种确诊来源对北爱尔兰黏多糖贮积症(MPS)进行了一项流行病学研究,并估算了1958年至1985年期间的发病率。MPS 1H(胡尔勒表型)的发病率约为每76,000例活产中有1例;MPS 1 H/S(胡尔勒/谢伊表型)为每280,000例中有1例;MPS II(亨特综合征)为每140,000例活产中有1例(每72,000例男性活产中有1例);MPS III(桑菲利波综合征)为每280,000例中有1例;MPS IV A(莫尔基奥综合征A型)为每76,000例中有1例。在研究期间未确诊MPS IS(谢伊表型)、MPS IV B(莫尔基奥综合征B型)或MPS VI(马罗泰克斯-拉米综合征)的病例。根据胎盘组织学检查和对父母双方的酶学研究,认为3例近亲父母所生的非免疫性胎儿水肿病例是由于β-葡萄糖醛酸酶缺乏(MPS VII)所致,但未确诊MPS VII的存活病例。所有类型黏多糖贮积症的总体发病率约为每25,000例活产中有1例。并与其他已发表研究得出的发病率估计值进行了比较。

相似文献

1
Incidence of the mucopolysaccharidoses in Northern Ireland.北爱尔兰黏多糖贮积症的发病率。
Hum Genet. 1997 Dec;101(3):355-8. doi: 10.1007/s004390050641.
2
Incidence of the mucopolysaccharidoses in Western Australia.西澳大利亚黏多糖贮积症的发病率。
Am J Med Genet A. 2003 Dec 15;123A(3):310-3. doi: 10.1002/ajmg.a.20314.
3
Cumulative incidence rates of the mucopolysaccharidoses in Germany.德国黏多糖贮积症的累积发病率
J Inherit Metab Dis. 2005;28(6):1011-7. doi: 10.1007/s10545-005-0112-z.
4
Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004.1984 - 2004年台湾黏多糖贮积症的发病率
Am J Med Genet A. 2009 May;149A(5):960-4. doi: 10.1002/ajmg.a.32781.
5
Epidemiology of mucopolysaccharidoses.黏多糖贮积症的流行病学
Mol Genet Metab. 2017 Jul;121(3):227-240. doi: 10.1016/j.ymgme.2017.05.016. Epub 2017 May 26.
6
Estimated birth prevalence of mucopolysaccharidoses in Brazil.巴西黏多糖贮积症的预估出生患病率。
Am J Med Genet A. 2020 Mar;182(3):469-483. doi: 10.1002/ajmg.a.61456. Epub 2020 Jan 11.
7
Further electroretinographic studies of patients with mucopolysaccharidoses.黏多糖贮积症患者的进一步视网膜电图研究。
Birth Defects Orig Artic Ser. 1971 Mar;7(3):32-40.
8
Mucopolysaccharidoses and the eye.黏多糖贮积症与眼睛。
Surv Ophthalmol. 2006 Jan-Feb;51(1):1-17. doi: 10.1016/j.survophthal.2005.11.007.
9
Prevalence rates of mucopolysaccharidoses in Poland.波兰黏多糖贮积症的患病率。
J Appl Genet. 2015 May;56(2):205-10. doi: 10.1007/s13353-014-0262-5. Epub 2014 Dec 4.
10
[Mucopolysaccharidosis: clinical features, diagnosis and management].[黏多糖贮积症:临床特征、诊断与管理]
Rev Chil Pediatr. 2016 Jul-Aug;87(4):295-304. doi: 10.1016/j.rchipe.2015.10.004. Epub 2015 Nov 21.

引用本文的文献

1
The Birth Prevalence of Mucopolysaccharidosis Types I, II, III, IVA, VI, and VII in the Republic of Kazakhstan Between 1984 and 2023.1984年至2023年哈萨克斯坦共和国I型、II型、III型、IVA 型、VI型和VII型黏多糖贮积症的出生患病率
Diagnostics (Basel). 2025 Mar 10;15(6):679. doi: 10.3390/diagnostics15060679.
2
Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme.用于活性rhGALNS酶体外和体内持续释放的水凝胶递送装置
Pharmaceuticals (Basel). 2023 Jun 27;16(7):931. doi: 10.3390/ph16070931.
3
A Neonate with Mucopolysaccharidosis Type VII with Intractable Ascites.
一名患有VII型黏多糖贮积症并伴有顽固性腹水的新生儿。
AJP Rep. 2023 Mar 16;13(1):e25-e28. doi: 10.1055/a-2028-7784. eCollection 2023 Jan.
4
Hurler Syndrome: Orofacial Clinical Findings.黏多糖贮积症I型:口面部临床表现。
Cureus. 2023 Jan 3;15(1):e33313. doi: 10.7759/cureus.33313. eCollection 2023 Jan.
5
Twenty years of Colombian experience with enzymatic screening in patients with features of mucopolysaccharidosis.哥伦比亚对具有黏多糖贮积症特征患者进行酶筛查的二十年经验。
JIMD Rep. 2022 Jul 28;63(5):475-483. doi: 10.1002/jmd2.12313. eCollection 2022 Sep.
6
Quantification of Idua Enzymatic Activity Combined with Observation of Phenotypic Change in Zebrafish Embryos Provide a Preliminary Assessment of Mutated Correlated with Mucopolysaccharidosis Type I.对艾杜糖醛酸酶(Idua)酶活性进行定量分析,并结合对斑马鱼胚胎表型变化的观察,为与I型黏多糖贮积症相关的突变提供了初步评估。
J Pers Med. 2022 Jul 23;12(8):1199. doi: 10.3390/jpm12081199.
7
Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA.α-艾杜糖醛酸-2-硫酸酯酶替代疗法对韩国IVA型黏多糖贮积症患者的临床特征及疗效
Mol Genet Metab Rep. 2022 Apr 15;31:100869. doi: 10.1016/j.ymgmr.2022.100869. eCollection 2022 Jun.
8
The GALNS p.P77R variant is a probable Gujarati-Indian founder mutation causing Mucopolysaccharidosis IVA syndrome.GALNS p.P77R 变异是引起黏多糖贮积症 IVA 综合征的一种可能的古吉拉特印度裔人群的 founder 突变。
BMC Genomics. 2022 Jun 21;23(1):458. doi: 10.1186/s12864-022-08693-4.
9
Assessment of the function and morphology of the thyroid gland in paediatric patients treated with enzyme replacement therapy due to selected storage diseases - preliminary results of our own research and a review of the literature.评估因选定的贮积病而接受酶替代治疗的儿科患者的甲状腺功能和形态-我们自己的研究的初步结果和文献复习。
Pediatr Endocrinol Diabetes Metab. 2022;28(2):114-122. doi: 10.5114/pedm.2022.112860.
10
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.Galactosidase enzyme replacement therapy for mucopolysaccharidosis type VI.
Cochrane Database Syst Rev. 2021 Sep 17;9(9):CD009806. doi: 10.1002/14651858.CD009806.pub3.